West Pharmaceutical Services Inc. (NYSE: WST) announced that Eric M. Green has informed the board of directors of his plans to retire from his positions as president, chief executive officer and chair of the board once a successor is hired.

The board is working with an executive recruiting firm to find Green's replacement, with the transition expected to occur in the second half of 2026. The company reaffirmed its financial guidance issued February 12, 2026.

Green has served as president and CEO since April 2015 and became chair of the board in May 2022. During his 11-year tenure, the company more than doubled its sales and achieved total shareholder return of approximately 350%, according to Lead Independent Director Robert F. Friel.

"After serving 11 years as the Company's 6th CEO over the past century, it is time for someone else to take over the leadership of West," Green said in the announcement.

West Pharmaceutical Services, headquartered in Exton, Pennsylvania, provides injectable drug containment and delivery solutions. The company operates 50 sites including 25 manufacturing facilities worldwide and generated $3.07 billion in net sales in fiscal year 2025.

The company serves as a supplier to pharmaceutical companies, delivering over 41 billion components and devices annually. West trades on the New York Stock Exchange and is included in the S&P 500 index.